biocytogen

Chinese biomedical CRO seals $77m fundraising for R&D push

Animal gene modifier Beijing Biocytogen managed to draw on both government and private capital for its Series D funding round.

August 08, 2019

Chinese animal gene modifier set to close $79m funding

Biocytogen delivers gene-modified mice to speed up development in the pharmaceutical industry. Riding the momentum of biotech development in China, the firm expects to IPO within three years.

July 18, 2019